Digitalis glycosides may be a safe and tolerable addition to optimal guideline medical therapy to reduce worsening heart ...

Digoxin, a cardiac glycoside derived from the foxglove plant, has been a mainstay of treatment in systolic heart failure and in rate control for atrial fibrillation. By inhibiting the cardiac ...

UB researchers have identified for the first time an enzyme in the foxglove plant that is responsible for the production of compounds needed to make the heart failure drug digoxin. The breakthrough ...

Digoxin now deserves to be considered first-line therapy for long-term heart rate control in older patients with permanent atrial fibrillation and symptoms of heart failure, investigators on a new ...

Analyses supporting the use of digitalis glycosides in patients with heart failure were presented in a Late-Breaking Science session today at Heart Failure 2026.

Oct. 30, 2002 — Digoxin may pose a risk of death for women with heart failure, according to a retrospective analysis published in the Oct. 31 issue of the New England Journal of Medicine. Yet ...

A trial by AIIMS shows digoxin may reduce worsening heart failure in rheumatic heart disease patients, offering a low-cost ...

A low dose of digoxin ensures that people with heart failure are hospitalized and die less frequently. This emerges from three studies led by UMCG cardiologists Dirk Jan van Veldhuisen, Kevin Damman, ...

Foxglove, a flowering plant long feared for its toxicity, became an unlikely source of a widely studied heart drug. Digoxin, a cardiac glycoside associated in modern medicine with Digitalis species ...

To the Editor: The report by Rathore et al. (Oct. 31 issue) 1 emphasizes differences according to sex in the outcomes of digoxin therapy in patients with congestive heart failure. Their post hoc ...

At present, digoxin should not be recommended for the treatment of patients with mild-to-moderate diastolic HF with preserved LVEF of greater than 45% in sinus rhythm This was an ancillary study ...